Bydureon Related Published Studies
Well-designed clinical trials related to Bydureon (Exenatide)
Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients
with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial
data. [2013]
Exenatide and the treatment of patients with Parkinson's disease. [2013]
Effects of HbA1c and weight reduction on blood pressure in patients with type 2
diabetes mellitus treated with exenatide*. [2012]
Investigation of the haemodynamic effects of exenatide in healthy male subjects. [2012]
Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes. [2009]
Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic
drug-naive patients with type 2 diabetes: a randomized, double-blind,
placebo-controlled, parallel-group study. [2008]
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and
glucagon secretion, gastric emptying, and caloric intake: a randomized,
cross-over study. [2008]
The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. [2007]
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and
hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data
from the open-label, uncontrolled extension of three double-blind,
placebo-controlled trials. [2007]
Effects of once-weekly dosing of a long-acting release formulation of exenatide
on glucose control and body weight in subjects with type 2 diabetes. [2007]
Mathematical modeling shows exenatide improved beta-cell function in patients
with type 2 diabetes treated with metformin or metformin and a sulfonylurea. [2006]
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients
with type 2 diabetes treated with metformin and a sulfonylurea. [2005]
Well-designed clinical trials possibly related to Bydureon (Exenatide)
Pharmacokinetic properties and effects of PT302 after repeated oral glucose
loading tests in a dose-escalating study. [2014]
Diabetes medications and body weight. [2009]
Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for
the treatment of type 2 diabetes. [2008]
Other research related to Bydureon (Exenatide)
Evaluation of exenatide versus insulin glargine for the impact on endothelial
functions and cardiovascular risk markers. [2014]
Motor and cognitive advantages persist 12 months after exenatide exposure in
Parkinson's disease. [2014]
Exenatide once weekly versus liraglutide once daily in patients with type 2
diabetes (DURATION-6): a randomised, open-label study. [2013]
Cardioprotective effects of exenatide in patients with ST-segment-elevation
myocardial infarction undergoing primary percutaneous coronary intervention:
results of exenatide myocardial protection in revascularization study. [2013]
Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes
mellitus. [2013]
Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a
randomized, open label study. [2013]
Once weekly exenatide: efficacy, tolerability and place in therapy. [2013]
Exenatide once weekly versus liraglutide once daily in patients with type 2
diabetes (DURATION-6): a randomised, open-label study. [2013]
Addition of exenatide twice daily to basal insulin for the treatment of type 2
diabetes: clinical studies and practical approaches to therapy. [2012]
Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical
results in subgroups of patients using different concomitant medications. [2012]
Use of concomitant glucose-lowering therapies and associated treatment results
observed in clinical trials of twice-daily exenatide. [2012]
Baseline factors associated with glycemic control and weight loss when exenatide
twice daily is added to optimized insulin glargine in patients with type 2
diabetes. [2012]
Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists
compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus:
a systematic review and meta-analysis. [2011]
Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the
clinical trials. [2011]
Other possibly related research studies
Effects of glucagon-like peptide-1 receptor agonists on body weight: a
meta-analysis. [2012]
Liraglutide for the treatment of type 2 diabetes. [2011]
Comparison of liraglutide versus other incretin-related anti-hyperglycaemic
agents. [2012]
Liraglutide in oral antidiabetic drug combination therapy. [2012]
The design of the liraglutide clinical trial programme. [2012]
Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in
development for treatment of type 2 diabetes mellitus in adults. [2012]
Drug treatment of obesity. [2011]
The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2
diabetes: a review. [2011]
Incretin treatment and risk of pancreatitis in patients with type 2 diabetes
mellitus: systematic review and meta-analysis of randomised and non-randomised
studies. [2014]
The potential risks of pancreatitis and pancreatic cancer with GLP-1-based
therapies are far outweighed by the proven and potential (cardiovascular)
benefits. [2013]
GLP-1R agonist therapy for diabetes: benefits and potential risks. [2013]
Weight change with liraglutide and comparator therapies: an analysis of seven
phase 3 trials from the liraglutide diabetes development programme. [2013]
Combination therapies of DPP4 inhibitors and GLP1 analogues with insulin in type
2 diabetic patients: a systematic review. [2013]
Pharmacological management of obesity in pediatric patients. [2015]
Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in
type 1 diabetes in a closed loop setting with ePID algorithm. [2014]
Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal
insulin in type 2 diabetes. [2014]
|